ADARx Pharmaceuticals is a newly launched next-wave genetic medicine company focusing on oligonucleotide therapeutics for inhibition, degradation and base editing of mRNA transcripts. With RNA as the target of our drug discovery, we are capable of working on a wide range of diseases and are currently focusing on genetic, cardiometabolic, and central nervous system (CNS) diseases. We are driven by our mission to turn cutting-edge science into life-saving therapeutics and our desire to provide hope for patients with intractable disease.
We are well-financed with backup from a group of renowned VC funds, and our brand-new laboratory is located in San Diego, California.
We are well-financed with backup from a group of renowned VC funds, and our brand-new laboratory is located in San Diego, California.
Location: Canada
Employees: 11-50
Total raised: $321M
Founded date: 2019
Investors 5
| Date | Name | Website |
| - | OrbiMed | orbimed.co... |
| 13.08.2023 | TCG Crosso... | tcgcrossov... |
| 04.11.2023 | HBM Partne... | hbmpartner... |
| 10.03.2024 | Bain Capit... | baincapita... |
| 15.09.2021 | SR One | srone.com |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 10.08.2023 | Series C | $200M | - |
| 24.01.2023 | Series B | $46M | - |
| 09.08.2021 | - | $75M | - |
Mentions in press and media 17
| Date | Title | Description |
| 13.10.2025 | Ascenta Capital: Final Close Of $325 Million Inaugural Fund | Ascenta Capital announced the closing of its inaugural fund at $325 million. The firm is dedicated to investing in biotechnology companies that are in the development stages of creating multiple medicines. This significant financial milesto... |
| 10.08.2023 | ADARx Pharmaceuticals closes $200M Series C round to advance their clinical programs and pipeline of innovative mRNA silencing/editing candidates | - |
| 10.08.2023 | ADARx Pharmaceuticals Raises $200M in Series C Financing | ADARx Pharmaceuticals, Inc., a San Diego, CA-based clinical stage biotechnology company developing next generation RNA therapeutics, closed a $200m Series C financing. The round was led jointly by Bain Capital Life Sciences and TCGX and als... |
| 09.08.2023 | ADARx Pharmaceuticals Announces Oversubscribed $200 Million Series C Financing | - |
| 30.01.2023 | 50 recently-funded startups to watch in 2023 | With the ongoing economic downturn and fear of a recession, tech startups have been hit hard as investors pulled back from new venture deals and reduce their investment in startups with exposure to recession. Further expounding on the fundi... |
| 24.01.2023 | California-based biotech company ADARx Pharmaceuticals raises USD 46 million in Series B1 funding | SAN DIEGO — To accelerate its drug development pipeline as the firm’s first product approaches the clinic, ADARx Pharmaceuticals, Inc., a clinical-stage biotechnology company creating RNA-targeting medicines, announced the conclusion of a U... |
| 23.01.2023 | Adarx Pharmaceuticals closes $46M Series B round to develop their RNA targeting platform | - |
| 23.01.2023 | ADARx Pharmaceuticals Takes $46M | San Diego-based ADARx Pharmaceuticals has raised $46M in a Series B-1 funding, the company said on Friday. The funding was led by Ascenta Capital, and also included OrbiMed Advisors, SR One Capital Management, Lilly Asia Ventures, and Siron... |
| 20.01.2023 | ADARx Pharmaceuticals Inks $46M Series B-1 | SAN DIEGO, CA, ADARx Pharmaceuticals, a clinical stage biotechnology company, announced the close of a $46 million Series B-1 financing. >> Click here for more funding data on ADARx Pharmaceuticals >> To export ADARx Pharmac... |
| 20.01.2023 | ADARx Pharmaceuticals Raises $46M in Series B-1 Financing | ADARx Pharmaceuticals, a San Diego, CA-based clinical stage biotechnology company developing RNA-targeting therapeutics, raised $46M in Series B-1 funding. The round was led by Ascenta Capital with participation from OrbiMed Advisors, SR On... |
Show more